Evidence map›Paper›PMID 23975429›Full record

ArticleOncogene2014

Ebp1 activates podoplanin expression and contributes to oral tumorigenesis.

Y Mei, P Zhang, H Zuo, D Clark, R Xia, J Li, Z Liu, L Mao

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Podoplanin in Inflammation and Cancer.International journal of molecular sciences · 2019
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Y MeiDepartment of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, University of Maryland, Baltimore, MD, USA.
P ZhangDepartment of Oral and Maxillofacial Surgery, Ninth People's Hospital, School of Stomatoloty, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatoloty and Shanghai Research Institute of Stomatology, Shanghai, China.
H ZuoDepartment of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, University of Maryland, Baltimore, MD, USA.
D ClarkDepartment of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, University of Maryland, Baltimore, MD, USA.
R XiaDepartment of Oral and Maxillofacial Surgery, Ninth People's Hospital, School of Stomatoloty, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatoloty and Shanghai Research Institute of Stomatology, Shanghai, China.
J LiDepartment of Oral and Maxillofacial Surgery, Ninth People's Hospital, School of Stomatoloty, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatoloty and Shanghai Research Institute of Stomatology, Shanghai, China.
Z LiuMarlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
L Mao1] Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, University of Maryland, Baltimore, MD, USA [2] Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
University of Maryland, Baltimore · USShanghai Ninth People's Hospital · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Podoplanin is highly expressed in human cancers. However, mechanisms regulating podoplanin expression remain elusive. Here we show that podoplanin promotes tumorigenesis of oral squamous cell carcinoma (OSCC) and precancerous cells both in vitro and in vivo, and the ErbB3-binding protein-1 (Ebp1) can be activated in oral tumorigenesis and can serve as a transcriptional activator to drive podoplanin expression in the malignant progression. Most of the OSCC cell lines have no detectable podoplanin protein in low-density cultures. However, the protein becomes detectable in high-density cultures and is required for in-vivo tumor formation of OSCC and oral premalignancies. In a high-density culture condition, podoplanin expression can be triggered at both mRNA and protein levels. In this condition, we showed that Ebp1 is upregulated, translocated from the cytoplasm to the nucleus and binds to the podoplanin promoter to result in a dramatic increase of podoplanin mRNA and protein. Ebp1 downregulation significantly reduced podoplanin expression levels in OSCC cells with a decreased anchorage-dependent growth, invasion and wound healing. Conversely, Ebp1 overexpression enhanced these malignant features through podoplanin upregulation both in vitro and in vivo. In 81 patients with oral premalignant lesions, we found that Ebp1 expression is strongly related to OSCC development. We conclude that Ebp1 has a key role in the upregulation of podoplanin and may contribute to oral tumorigenesis.

Indexed as

Gene Expression Regulation, NeoplasticAdaptor Proteins, Signal TransducingAnimalsCarcinoma, Squamous CellCell CommunicationCell Line, TumorCell Transformation, NeoplasticDisease Models, AnimalFemaleHumansMaleMembrane GlycoproteinsMiceMouth NeoplasmsPodoplaninPromoter Regions, GeneticAdaptor Proteins, Signal TransducingMembrane GlycoproteinsPA2G4 protein, humanPDPN protein, humanPodoplaninRNA-Binding Proteins

Identifiers

PMID23975429
OpenAlexW2001524537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.